Pituitary Acrogigantism: From the Past to the Future

Area of Science:

• Endocrinology
• Genetics
• Pediatric Oncology

Background:

• Pituitary acrogigantism is a rare, severe condition caused by excess growth hormone (GH) during childhood/adolescence.
• It is a significant manifestation of acromegaly, often stemming from pituitary adenomas, sometimes with hyperplasia.
• Rarely, it can be caused by peripheral neuroendocrine tumors secreting GH-releasing hormone.

Purpose of the Study:

• To summarize the genetic underpinnings and clinical presentation of pituitary acrogigantism.
• To highlight the importance of early diagnosis and rapid hormonal control in managing this condition.
• To discuss the challenges in multimodal therapy, including the use of off-label medications in pediatric patients.

Main Methods:

• Review of existing literature on pituitary acrogigantism.
• Analysis of genetic causes, including germline alterations and specific gene variants.
• Description of clinical features, age of onset, and treatment modalities.

Main Results:

• Approximately 50% of patients have identifiable germline genetic alterations (e.g., AIP gene variants, X-linked acrogigantism, McCune-Albright syndrome).
• Genetic factors lead to aggressive, early-onset somatotropinomas with high GH secretion and resistant IGF-1 elevation.
• Specific genetic causes have distinct age-of-onset profiles: X-linked acrogigantism by 36 months, McCune-Albright syndrome before 5 years, and AIP-related cases around 16 years.

Conclusions:

• Pituitary acrogigantism has a strong genetic component, influencing tumor behavior and age of onset.
• Prompt diagnosis and effective GH control are essential to manage final height and disease severity.
• Multimodal treatment approaches are often necessary, posing challenges particularly with pediatric-specific therapies.